Locally Advanced Solid Tumors research hub

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

This study looks at a new drug, repotrectinib, for children and young adults (up to 25) with certain advanced cancers. It checks if the drug is safe and helps shrink tumours that have specific genetic changes called ALK, ROS1, or NTRK.